Phase II trial of oral β-all trans-retinoic acid in hepatocellular carcinoma (SWOG 9157)

Frank L. Meyskens, Joth Jacobson, Bichlien Nguyen, Geoffrey R. Weiss, David R Gandara, John S. MacDonald

Research output: Contribution to journalArticlepeer-review

18 Scopus citations


Twenty-nine chemotherapy-naive patients with primary hepatocellular carcinoma were treated with oral β-all transretinoic acid (retinoic acid, TRA 50 mg/m2 tid) on a 3-week on/one week off schedule until progression or grade 3 or 4 toxicity. Eligibility requirements allowed abnormal liver function tests as long as the creatinine and bilirubin levels were normal. No responses were seen and the median survival was four months. Grade 3 side effects occurred in 11 patients and grade 4 in four and included a wide range of toxicities. The results indicate that oral TRA is ineffective against primary hepatocellular carcinoma and suggest that dose-modification of this retinoid may be required in patients with significant malignant hepatic involvement.

Original languageEnglish (US)
Pages (from-to)171-173
Number of pages3
JournalInvestigational New Drugs
Issue number2
StatePublished - 1998


  • Hepatocellular carcinoma
  • Hepatoma
  • Retinoic acid
  • Vitamin A

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology


Dive into the research topics of 'Phase II trial of oral β-all trans-retinoic acid in hepatocellular carcinoma (SWOG 9157)'. Together they form a unique fingerprint.

Cite this